Salinosporamide A is a potent proteasome inhibitor being studied as a potential anticancer agent. It entered phase I human clinical trials for the treatment of multiple myeloma, only three years after its discovery in 2003. This marine natural product is produced by the obligate marine bacteria Salinispora tropica and Salinispora arenicola, which are found in ocean sediment. Salinosporamide A belongs to a family of compounds, known collectively as salinosporamides, which possess a densely functionalized γ-lactam-β-lactone bicyclic core.

CAS：437742-34-2
中文别名：
英文别名：MARIZOMIB;(1S,2R,5R)-2-(2-chloroethyl)-5-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-1-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione;NPI-0052;UNII-703P9YDP7F;
分子式：C15H20ClNO4
分子量：313.777
精确质量：313.108
Psa：79.12
Logp：1.4087

UNII：703P9YDP7F

储存条件：4ºC